Filing Flows

Filing Flows › 8-K events › Pacific Biosciences of California

Pacific Biosciences of California: results of operations

Form 8-K filed Nov 4, 2026 · items 2.02, 5.02

CEO changesPacBio Announces Third Quarter 2026 Financial Results

What the filing says

PacBio Announces Third Quarter 2026 Financial Results PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 5.02: −0.1% next session across 39,174. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Pacific Biosciences of California at a glance

Latest quarterQ3 2026
Revenue$40.6M
Revenue Y/Y+6%
Operating margin-91.2%
IndustryLaboratory Analytical Instruments

Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%. The chart follows the revenue to costs, profit and cash.

Pacific Biosciences of California: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.